// App-Quantinova.ai

11043 : Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial.

Researchers

Presenter

  • Julia Katharina Neugebauer

Principal Investigators

  • Brigitte Kathrin Rack

  • Bernadette Anna Sophia Jaeger

  • Ekkehard von Abel

  • Andreas Schneeweiss

  • Matthias W. Beckmann

  • Klaus Pantel

  • Wolfgang Janni

  • Ulrich Andergassen

  • Aurelia Pestka

  • Peter A. Fasching

  • Thomas W. P. Friedl

  • Doraid Mouarrawy

  • Michael R. Clemens

  • Gabriele Ziemendorff

  • Georg Heinrich

Medical Centers

  • Frauenklinik der Universitat Erlangen, Erlangen, Germany

  • Department of Gynecology and Obstetrics Ludwig-MaximiliansUniversity, Munich, Germany

  • Gynakologisch-Onkologische Praxis, Hannover, Germany

  • Klinikum Ludwigsburg, Ludwigsburg, Germany

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • II. Medical Clinic & Institute of Tumor Biology, Campus Forschung, University Hospital Hamburg-Eppendorf, Hamburg, Germany

  • Klinikum Bremerhaven-Reinkenheide, Bremerhaven, Germany

  • Klinikum Schwabisch-Gmund, Schwabisch-Gmund, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • Department of Obstetrics and Gynecology, University Erlangen, Erlangen, Germany

  • Klinikum Mutterhaus, Trier, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Gemcitabine

  • Fluorescein sodium

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved